<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501852</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237A2205</org_study_id>
    <nct_id>NCT00501852</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4 Period Incomplete Block Cross-over, Multi-center, Multiple Dose (7 Days) Dose-ranging Study to Assess the Efficacy and Safety of 4 Doses of NVA237 in Patients With Stable COPD, Compared to Seven Days Treatment With Tiotropium (18μg Once Daily, Open Label) as an Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients
      with stable COPD, in comparison to an active comparator.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment</measure>
    <time_frame>Day 7</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Least Squares Means of FEV1 (L) at Day 1, by Timepoint</measure>
    <time_frame>Day 1</time_frame>
    <description>FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>NVA237 12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 25 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 50 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVA237 100 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium 18 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>single-dose dry-powder inhaler (SDDPI)</description>
    <arm_group_label>NVA237 12.5 µg</arm_group_label>
    <arm_group_label>NVA237 25 µg</arm_group_label>
    <arm_group_label>NVA237 50 µg</arm_group_label>
    <arm_group_label>NVA237 100 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single-dose dry-powder inhaler (SDDPI)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Handihaler inhaler</description>
    <arm_group_label>Tiotropium 18 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure.

          -  Patients with moderate to severe COPD according to the Gold Guidelines (2006).

          -  Patients who have smoking history of at least 10 pack years. Ten pack-years is defined
             as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.

          -  Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30%
             and &lt; 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity
             (FVC) &lt; 0.7 at Visit 2. For non-Japanese patients predicted FEV1 should be calculated
             according to Quanjer predictive equations [Quanjer PH 1993], for Japanese patients
             predicted FEV1 should be calculated according to Japanese Respiratory Society
             predictive tables [Japan Respiratory Society 2001].

        Exclusion Criteria:

          -  Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy
             test).

          -  Patients requiring oxygen therapy on a daily basis for chronic hypoxemia, or who have
             been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to
             Visit 1 or between Visit 1 and Visit 3.

          -  Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1.
             Patients who develop a respiratory tract infection during the screening period (up to
             Visit 3) must discontinue from the trial, but will be permitted to re-enroll at a
             later date (at least 6 weeks after the resolution of the respiratory tract infection).

          -  Patients who, in the judgment of the investigator or the responsible Novartis
             personnel, have a clinically relevant laboratory abnormality or a clinically
             significant condition such as (but not limited to) unstable ischemic heart disease,
             cancers, left ventricular failure, long term prednisone therapy, history of myocardial
             infarction, arrhythmia (all), narrow angle glaucoma, symptomatic prostatic hyperplasia
             or bladder-neck obstruction or moderate to severe renal impairment.

          -  Patients with a history of asthma indicated by (but not limited to):

               1. Blood eosinophil count &gt; 400/mm3

               2. Onset of symptoms prior to age 40 years.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Vilvoorde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Rueil-Malmaison,</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <results_first_submitted>December 22, 2010</results_first_submitted>
  <results_first_submitted_qc>December 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2011</results_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, Age≥40 yrs, Glycopyrronium Bromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 12.5µg</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 25µg</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 50µg</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NVA237 100µg</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Tiotropium</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>40-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent-to-Treat (mITT) population. The modified intent-to-treat (mITT) population included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 ug</title>
            <description>12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25 ug</title>
            <description>25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O3">
            <title>NVA237 50 ug</title>
            <description>50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O4">
            <title>NVA237 100 ug</title>
            <description>100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide</title>
            <description>18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing.</description>
          <population>Modified Intent-to-Treat (mITT) population. The modified intent-to-treat (mITT) population included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they received.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.317" spread="0.0145"/>
                    <measurement group_id="O2" value="1.333" spread="0.0151"/>
                    <measurement group_id="O3" value="1.374" spread="0.0148"/>
                    <measurement group_id="O4" value="1.385" spread="0.0148"/>
                    <measurement group_id="O5" value="1.243" spread="0.0156"/>
                    <measurement group_id="O6" value="1.370" spread="0.0145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Means of FEV1 (L) at Day 1, by Timepoint</title>
        <description>FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NVA237 12.5 ug</title>
            <description>12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O2">
            <title>NVA237 25 ug</title>
            <description>25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O3">
            <title>NVA237 50 ug</title>
            <description>50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O4">
            <title>NVA237 100 ug</title>
            <description>100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide</title>
            <description>18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Means of FEV1 (L) at Day 1, by Timepoint</title>
          <description>FEV1 was measured at 5, 15, 30 minutes, 1, 2, 3, 4, 5, 23 hours and 15 minutes, and 23 hours and 45 minutes post dose.</description>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: -45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.00"/>
                    <measurement group_id="O2" value="1.24" spread="0.00"/>
                    <measurement group_id="O3" value="1.24" spread="0.00"/>
                    <measurement group_id="O4" value="1.24" spread="0.00"/>
                    <measurement group_id="O5" value="1.24" spread="0.00"/>
                    <measurement group_id="O6" value="1.25" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: -15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.00"/>
                    <measurement group_id="O2" value="1.26" spread="0.00"/>
                    <measurement group_id="O3" value="1.25" spread="0.00"/>
                    <measurement group_id="O4" value="1.26" spread="0.00"/>
                    <measurement group_id="O5" value="1.26" spread="0.00"/>
                    <measurement group_id="O6" value="1.25" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.01"/>
                    <measurement group_id="O2" value="1.34" spread="0.01"/>
                    <measurement group_id="O3" value="1.34" spread="0.01"/>
                    <measurement group_id="O4" value="1.35" spread="0.01"/>
                    <measurement group_id="O5" value="1.26" spread="0.01"/>
                    <measurement group_id="O6" value="1.31" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.01"/>
                    <measurement group_id="O2" value="1.41" spread="0.01"/>
                    <measurement group_id="O3" value="1.41" spread="0.01"/>
                    <measurement group_id="O4" value="1.41" spread="0.01"/>
                    <measurement group_id="O5" value="1.27" spread="0.01"/>
                    <measurement group_id="O6" value="1.35" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.01"/>
                    <measurement group_id="O2" value="1.44" spread="0.01"/>
                    <measurement group_id="O3" value="1.44" spread="0.01"/>
                    <measurement group_id="O4" value="1.45" spread="0.01"/>
                    <measurement group_id="O5" value="1.28" spread="0.01"/>
                    <measurement group_id="O6" value="1.40" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.01"/>
                    <measurement group_id="O2" value="1.46" spread="0.01"/>
                    <measurement group_id="O3" value="1.46" spread="0.01"/>
                    <measurement group_id="O4" value="1.48" spread="0.01"/>
                    <measurement group_id="O5" value="1.28" spread="0.01"/>
                    <measurement group_id="O6" value="1.41" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.01"/>
                    <measurement group_id="O2" value="1.48" spread="0.01"/>
                    <measurement group_id="O3" value="1.50" spread="0.01"/>
                    <measurement group_id="O4" value="1.52" spread="0.01"/>
                    <measurement group_id="O5" value="1.31" spread="0.01"/>
                    <measurement group_id="O6" value="1.45" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.01"/>
                    <measurement group_id="O2" value="1.48" spread="0.01"/>
                    <measurement group_id="O3" value="1.49" spread="0.01"/>
                    <measurement group_id="O4" value="1.53" spread="0.01"/>
                    <measurement group_id="O5" value="1.30" spread="0.01"/>
                    <measurement group_id="O6" value="1.46" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.01"/>
                    <measurement group_id="O2" value="1.45" spread="0.01"/>
                    <measurement group_id="O3" value="1.49" spread="0.01"/>
                    <measurement group_id="O4" value="1.52" spread="0.01"/>
                    <measurement group_id="O5" value="1.30" spread="0.01"/>
                    <measurement group_id="O6" value="1.46" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.01"/>
                    <measurement group_id="O2" value="1.43" spread="0.01"/>
                    <measurement group_id="O3" value="1.44" spread="0.01"/>
                    <measurement group_id="O4" value="1.49" spread="0.01"/>
                    <measurement group_id="O5" value="1.28" spread="0.01"/>
                    <measurement group_id="O6" value="1.45" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 23 hours 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.01"/>
                    <measurement group_id="O2" value="1.29" spread="0.01"/>
                    <measurement group_id="O3" value="1.36" spread="0.01"/>
                    <measurement group_id="O4" value="1.37" spread="0.01"/>
                    <measurement group_id="O5" value="1.24" spread="0.01"/>
                    <measurement group_id="O6" value="1.35" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: 23 hours 45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.01"/>
                    <measurement group_id="O2" value="1.31" spread="0.01"/>
                    <measurement group_id="O3" value="1.37" spread="0.01"/>
                    <measurement group_id="O4" value="1.39" spread="0.01"/>
                    <measurement group_id="O5" value="1.25" spread="0.01"/>
                    <measurement group_id="O6" value="1.37" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.01"/>
                    <measurement group_id="O2" value="1.30" spread="0.01"/>
                    <measurement group_id="O3" value="1.36" spread="0.01"/>
                    <measurement group_id="O4" value="1.38" spread="0.01"/>
                    <measurement group_id="O5" value="1.24" spread="0.01"/>
                    <measurement group_id="O6" value="1.36" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVA237 12.5 ug</title>
          <description>12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
        <group group_id="E2">
          <title>NVA237 25 ug</title>
          <description>25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
        <group group_id="E3">
          <title>NVA237 50 ug</title>
          <description>50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
        <group group_id="E4">
          <title>NVA237 100 ug</title>
          <description>100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
        <group group_id="E6">
          <title>Tiotropium Bromide</title>
          <description>18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

